News

The use of digital health technology (DHT) is increasing worldwide. Clinical trials assessing available health tools for the ...
Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected ...
Q1 2025 Earnings Call Transcript May 15, 2025 Taysha Gene Therapies, Inc. reports earnings inline with expectations. Reported ...
Q1 2025 Earnings Call Transcript May 12, 2025 FibroGen, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $0.03. Operator: Good day and thank you for standing by.
Background Coronary artery disease (CAD) is linked to an increased risk of mild cognitive impairment (MCI). Effective and ...
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivere ...
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and ...
Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Financial Results and to provide the Business Update. This call is being recorded. My name is Gayle ...
Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructions). Please be advised today's conference is being recorded. I would not like to end the conference over to your ...
Tech entrepreneur, Erez Druk, and his wife, Gabi Meckler, a family physician, built Freed AI to help doctors save time taking ...
And, in the last few years, the growth of real-world data and a renewed drive towards ‘patient centricity’ means Medical Affairs finds itself at the heart of pharma’s new business model.
"Everyone in Tulsa depending on a 911 call should know that everything is happening as it should on the other end when seconds count. But multiple cases are calling that into question. Right now, we ...